Trial Outcomes & Findings for Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children (NCT NCT00183391)

NCT ID: NCT00183391

Last Updated: 2018-06-06

Results Overview

ADHD-RS Total Score Attention Deficit Hyperactivity Disorder Rating Scale. Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-54. Higher score indicates higher probability of diagnosis.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

232 participants

Primary outcome timeframe

up to 14 weeks

Results posted on

2018-06-06

Participant Flow

Participant milestones

Participant milestones
Measure
Atomoxetine Then Methylphenidate
Participants randomized to receive Atomoxetine until optimal response, then washed out and crossed-over to receive Methylphenidate.
Methylphenidate Then Atomoxetine
Participants randomized to receive Methylphenidate until optimal response, then washed out and crossed-over to receive Atomoxetine.
Block 1 - 5 Weeks
STARTED
108
124
Block 1 - 5 Weeks
COMPLETED
95
110
Block 1 - 5 Weeks
NOT COMPLETED
13
14
Crossover Placebo - 2 Weeks
STARTED
95
110
Crossover Placebo - 2 Weeks
COMPLETED
95
110
Crossover Placebo - 2 Weeks
NOT COMPLETED
0
0
Block 2 - 5 Weeks
STARTED
95
110
Block 2 - 5 Weeks
COMPLETED
91
108
Block 2 - 5 Weeks
NOT COMPLETED
4
2

Reasons for withdrawal

Reasons for withdrawal
Measure
Atomoxetine Then Methylphenidate
Participants randomized to receive Atomoxetine until optimal response, then washed out and crossed-over to receive Methylphenidate.
Methylphenidate Then Atomoxetine
Participants randomized to receive Methylphenidate until optimal response, then washed out and crossed-over to receive Atomoxetine.
Block 1 - 5 Weeks
Withdrawal by Subject
13
14
Block 2 - 5 Weeks
Withdrawal by Subject
4
2

Baseline Characteristics

Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Atomoxetine Then Methylphenidate
n=108 Participants
Participants randomized to receive Atomoxetine until optimal response, then washed out and crossed-over to receive Methylphenidate.
Methylphenidate Then Atomoxetine
n=124 Participants
Participants randomized to receive Methylphenidate until optimal response, then washed out and crossed-over to receive Atomoxetine.
Total
n=232 Participants
Total of all reporting groups
Age, Continuous
10.34 years
STANDARD_DEVIATION 2.61 • n=99 Participants
10.56 years
STANDARD_DEVIATION 2.83 • n=107 Participants
10.41 years
STANDARD_DEVIATION 2.72 • n=206 Participants
Sex: Female, Male
Female
27 Participants
n=99 Participants
36 Participants
n=107 Participants
63 Participants
n=206 Participants
Sex: Female, Male
Male
81 Participants
n=99 Participants
88 Participants
n=107 Participants
169 Participants
n=206 Participants

PRIMARY outcome

Timeframe: up to 14 weeks

Population: see participant flow section for participants that did not complete blocks

ADHD-RS Total Score Attention Deficit Hyperactivity Disorder Rating Scale. Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-54. Higher score indicates higher probability of diagnosis.

Outcome measures

Outcome measures
Measure
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
ADHD-RS Total Score
Block 1 Baseline Week 0
39.58 units on a scale
Standard Deviation 8.984
39.75 units on a scale
Standard Deviation 9.835
ADHD-RS Total Score
Block 1 End of Treatment Week 6
20.03 units on a scale
Standard Deviation 13.657
17.59 units on a scale
Standard Deviation 12.756
ADHD-RS Total Score
Block 2 Baseline Week 8
34.32 units on a scale
Standard Deviation 11.423
33.54 units on a scale
Standard Deviation 12.077
ADHD-RS Total Score
Blocks 2 End of Treatment Week 14
18.08 units on a scale
Standard Deviation 12.192
22.13 units on a scale
Standard Deviation 13.356

SECONDARY outcome

Timeframe: Measured at ends of treatments one and two

Outcome measures

Outcome measures
Measure
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
Treatment Preference Survey
Treatment Preference of ATX
41.8 percentage of participants
27.4 percentage of participants
Treatment Preference Survey
Treatment Preference of MPH
50.5 percentage of participants
51.9 percentage of participants

SECONDARY outcome

Timeframe: up to 14 weeks

Population: see participant flow section for participants that did not complete blocks

Attention deficit/hyperactivity disorder - hyperactivity/impulsivity (ADHD- H/I). Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-27. Higher score indicates higher probability of diagnosis.

Outcome measures

Outcome measures
Measure
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
ADHD - H/I
Block 1 Baseline Week 0
16.56 units on a scale
Standard Deviation 7.235
17.31 units on a scale
Standard Deviation 7.887
ADHD - H/I
Block 1 End of Treatment Week 6
7.82 units on a scale
Standard Deviation 7.159
7.24 units on a scale
Standard Deviation 7.083
ADHD - H/I
Block 2 Baseline 8
13.99 units on a scale
Standard Deviation 8.258
14.80 units on a scale
Standard Deviation 8.310
ADHD - H/I
Blocks 2 End of Treatment Week 14
6.67 units on a scale
Standard Deviation 5.818
8.87 units on a scale
Standard Deviation 7.651

SECONDARY outcome

Timeframe: up to 14 weeks

Population: see participant flow section for participants that did not complete blocks

Each item on the 18-item measure is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms), yielding a possible total score of 0-27. Higher score indicates higher probability of diagnosis.

Outcome measures

Outcome measures
Measure
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
ADHD-RS Inattention
Block 1 Baseline Week 0
23.30 units on a scale
Standard Deviation 3.524
22.44 units on a scale
Standard Deviation 4.027
ADHD-RS Inattention
Block 1 End of Treatment Week 6
12.32 units on a scale
Standard Deviation 7.889
10.35 units on a scale
Standard Deviation 7.172
ADHD-RS Inattention
Block 2 Baseline Week 8
20.33 units on a scale
Standard Deviation 5.525
18.74 units on a scale
Standard Deviation 5.572
ADHD-RS Inattention
Blocks 2 End of Treatment Week 14
11.09 units on a scale
Standard Deviation 7.103
13.26 units on a scale
Standard Deviation 7.398

SECONDARY outcome

Timeframe: up to 14 weeks

Population: see participant flow section for participants that did not complete blocks

The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.

Outcome measures

Outcome measures
Measure
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
Clinical Global Impressions (CGI)- Severity
Block 1 Baseline Week 0
5.14 units on a scale
Standard Deviation .756
5.09 units on a scale
Standard Deviation .716
Clinical Global Impressions (CGI)- Severity
Block 1 End of Treatment Week 6
3.20 units on a scale
Standard Deviation 1.641
2.83 units on a scale
Standard Deviation 1.446
Clinical Global Impressions (CGI)- Severity
Block 2 Baseline Week 8
4.75 units on a scale
Standard Deviation .938
4.55 units on a scale
Standard Deviation 1.233
Clinical Global Impressions (CGI)- Severity
Blocks 2 End of Treatment Week 14
2.94 units on a scale
Standard Deviation 1.458
3.43 units on a scale
Standard Deviation 1.460

SECONDARY outcome

Timeframe: up to 14 weeks

Population: see participant flow section for participants that did not complete blocks

Measure of social skills, higher score is better. This scale is based on t-scores and does not have psychometrics available.

Outcome measures

Outcome measures
Measure
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
Social Skills Rating Scale (SSRS)- Parent Version
Block 1 Baseline Week 0
82.71 t-score
Standard Deviation 28.414
77.96 t-score
Standard Deviation 22.779
Social Skills Rating Scale (SSRS)- Parent Version
Block 1 End of Treatment Week 6
91.07 t-score
Standard Deviation 35.350
88.57 t-score
Standard Deviation 26.099
Social Skills Rating Scale (SSRS)- Parent Version
Block 2 Baseline Week 8
78.58 t-score
Standard Deviation 21.112
82.35 t-score
Standard Deviation 28.698
Social Skills Rating Scale (SSRS)- Parent Version
Blocks 2 End of Treatment Week 14
91.07 t-score
Standard Deviation 33.887
87.96 t-score
Standard Deviation 19.501

SECONDARY outcome

Timeframe: up to 14 weeks

Population: see participant flow section for participants that did not complete blocks

Measure of conflict within the home over the past 24 hours. The CCI is a validated measure of family conflicts in the home and is completed by parents. It consists of 42 items (for boys) or 36 items (for girls) reflecting attention-seeking and conflictual behavior, as well as negativity and withdrawal. Items are scored as yes (1 point) or no (0 points). Mean score between 0 and 1 reported, with higher score indicating greater conflict.

Outcome measures

Outcome measures
Measure
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
Child Conflict Index (CCI)
Block 1 Baseline Week 0
.3224 units on a scale
Standard Deviation .19841
.3385 units on a scale
Standard Deviation .19795
Child Conflict Index (CCI)
Block 1 End of Treatment week 6
.2386 units on a scale
Standard Deviation .21233
.1978 units on a scale
Standard Deviation .20251
Child Conflict Index (CCI)
Block 1 End of Treatment Week 8
.3526 units on a scale
Standard Deviation .20878
.3078 units on a scale
Standard Deviation .20744
Child Conflict Index (CCI)
Blocks 2 End of Treatment Week 14
.2118 units on a scale
Standard Deviation .20053
.2304 units on a scale
Standard Deviation .18978

SECONDARY outcome

Timeframe: up to 14 weeks

Population: see participant flow section for participants that did not complete blocks

CPT Commissions, impulsive responses, higher score is worse. This scale is based on t-scores and does not have psychometrics available.

Outcome measures

Outcome measures
Measure
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
Continuous Performance Test (CPT)
Block 1 Baseline Week 0
51.3277 T-scores
Standard Deviation 9.73401
52.8976 T-scores
Standard Deviation 9.36961
Continuous Performance Test (CPT)
Block 1 End of Treatment Week 6
51.7005 T-scores
Standard Deviation 9.57790
51.1713 T-scores
Standard Deviation 9.96929
Continuous Performance Test (CPT)
Block 2 Baseline Week 8
59.8788 T-scores
Standard Deviation 8.82849
51.2159 T-scores
Standard Deviation 9.00827
Continuous Performance Test (CPT)
Blocks 2 End of Treatment Week 14
50.0763 T-scores
Standard Deviation 11.16765
49.1616 T-scores
Standard Deviation 10.02259

SECONDARY outcome

Timeframe: up to 14 weeks

Population: see participant flow section for participants that did not complete blocks

Children's Sleep Problems Severity, sum of scores, higher is worse.The scale assessed contains 16 items, each scored 0 to 3, with 0 representing no problems and 3 representing daily problems. total range from 0 to 48. This score does not have psychometrics available.

Outcome measures

Outcome measures
Measure
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
Children's Sleep Questionnaire
Block 1 Baseline Week 0
5.14 units on a scale
Standard Deviation .756
5.09 units on a scale
Standard Deviation .716
Children's Sleep Questionnaire
Block 1 End of Treatment Week 6
3.20 units on a scale
Standard Deviation 1.641
2.83 units on a scale
Standard Deviation 1.446
Children's Sleep Questionnaire
Block 2 Baseline Week 8
4.75 units on a scale
Standard Deviation .938
4.55 units on a scale
Standard Deviation 1.233
Children's Sleep Questionnaire
Blocks 2 End of Treatment Week 14
2.94 units on a scale
Standard Deviation 1.458
3.43 units on a scale
Standard Deviation 1.460

SECONDARY outcome

Timeframe: up to 14 weeks

Population: see participant flow section for participants that did not complete blocks

Affective problems. This scale consists of 8 items, scored 0-3, with 0 representing no problems and 3 representing extreme problems. This analysis presents sum of scores, higher is worse. Full range from 0 to 24. This score does not have psychometrics available.

Outcome measures

Outcome measures
Measure
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
Assessment of Affective Range (AAR)
Block 1 Baseline Week 0
11.2609 units on a scale
Standard Deviation 2.85251
10.6905 units on a scale
Standard Deviation 3.44309
Assessment of Affective Range (AAR)
Block 1 End of Treatment Week 6
10.6889 units on a scale
Standard Deviation 2.83495
10.8257 units on a scale
Standard Deviation 2.77170
Assessment of Affective Range (AAR)
Block 2 Baseline Week 8
9.7108 units on a scale
Standard Deviation 2.99402
10.1400 units on a scale
Standard Deviation 3.06831
Assessment of Affective Range (AAR)
Blocks 2 End of Treatment Week 14
10.9886 units on a scale
Standard Deviation 2.69736
10.9286 units on a scale
Standard Deviation 3.02652

SECONDARY outcome

Timeframe: up to 14 weeks

Population: see participant flow section for participants that did not complete blocks

Modified Yale Global Tic Severity Scale, sum, higher is worse. This score does not have psychometrics available. The Yale Global Tic Severity Scale (YGTSS) is a semistructured clinician-rated instrument that assesses the severity and frequency of motor and phonic tics over the previous week. Five index scores are obtained during the assessment, where higher scores indicate greater frequency or severity. These indices are: Total Motor Tic Score (0-25), Total Phonic Tic Score (0-25), Total Tic Score (0-50) Overall Impairment Rating (0-50).

Outcome measures

Outcome measures
Measure
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
Tics: Total Motor
Block 1 Baseline Week 0
.196 units on a scale
Standard Deviation .7727
.111 units on a scale
Standard Deviation .4297
Tics: Total Motor
Block 1 End of Treatment Week 6
.053 units on a scale
Standard Deviation .2941
1.342 units on a scale
Standard Deviation 11.3544
Tics: Total Motor
Block 2 Baseline Week 8
.000 units on a scale
Standard Deviation .0000
.214 units on a scale
Standard Deviation .8494
Tics: Total Motor
Blocks 2 End of Treatment Week 14
.160 units on a scale
Standard Deviation .7656
.143 units on a scale
Standard Deviation .6686

SECONDARY outcome

Timeframe: up to 14 weeks

Population: see participant flow section for participants that did not complete blocks

Modified Yale Global Tic Severity Scale, sum, higher is worse. This score does not have psychometrics available. The Yale Global Tic Severity Scale (YGTSS) is a semistructured clinician-rated instrument that assesses the severity and frequency of motor and phonic tics over the previous week. Five index scores are obtained during the assessment, where higher scores indicate greater frequency or severity. These indices are: Total Motor Tic Score (0-25), Total Phonic Tic Score (0-25), Total Tic Score (0-50) Overall Impairment Rating (0-50).

Outcome measures

Outcome measures
Measure
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
Tics: Total Phonic
Block 2 Baseline Week 8
.039 units on a scale
Standard Deviation .1960
.057 units on a scale
Standard Deviation .2892
Tics: Total Phonic
Block 1 Baseline Week 0
.161 units on a scale
Standard Deviation .5649
.028 units on a scale
Standard Deviation .1655
Tics: Total Phonic
Block 1 End of Treatment Week 6
.018 units on a scale
Standard Deviation .1325
1.329 units on a scale
Standard Deviation 11.3542
Tics: Total Phonic
Blocks 2 End of Treatment Week 14
.060 units on a scale
Standard Deviation .3136
.016 units on a scale
Standard Deviation .1260

SECONDARY outcome

Timeframe: up to 14 weeks

Population: see participant flow section for participants that did not complete blocks

Modified Yale Global Tic Severity Scale, sum, higher is worse. This score does not have psychometrics available. The Yale Global Tic Severity Scale (YGTSS) is a semistructured clinician-rated instrument that assesses the severity and frequency of motor and phonic tics over the previous week. Five index scores are obtained during the assessment, where higher scores indicate greater frequency or severity. These indices are: Total Motor Tic Score (0-25), Total Phonic Tic Score (0-25), Total Tic Score (0-50) Overall Impairment Rating (0-50).

Outcome measures

Outcome measures
Measure
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
Tics: Total Impairment
Block 1 Baseline Week 0
5.304 units on a scale
Standard Deviation 22.4936
.292 units on a scale
Standard Deviation 1.8571
Tics: Total Impairment
Block 1 End of Treatment Week 6
1.737 units on a scale
Standard Deviation 13.1129
.132 units on a scale
Standard Deviation 1.1471
Tics: Total Impairment
Block 2 Baseline Week 8
.000 units on a scale
Standard Deviation .0000
.643 units on a scale
Standard Deviation 3.1762
Tics: Total Impairment
Blocks 2 End of Treatment Week 14
.500 units on a scale
Standard Deviation 2.9014
.397 units on a scale
Standard Deviation 2.2543

SECONDARY outcome

Timeframe: up to 14 weeks

Population: see participant flow section for participants that did not complete blocks

Systolic blood pressure - the amount of pressure in arteries during contraction of the heart muscle Normal range varies by age, sex, height and weight and can range from 80mm Hg to 130mmHg

Outcome measures

Outcome measures
Measure
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
Vital Signs - Systolic Blood Pressure
Block 1 Baseline Week 0
101.11 mm HG
Standard Deviation 11.877
101.60 mm HG
Standard Deviation 11.261
Vital Signs - Systolic Blood Pressure
Block 1 End of Treatment Week 6
102.10 mm HG
Standard Deviation 12.442
103.29 mm HG
Standard Deviation 12.374
Vital Signs - Systolic Blood Pressure
Block 2 Baseline Week 8
99.74 mm HG
Standard Deviation 12.199
101.29 mm HG
Standard Deviation 12.629
Vital Signs - Systolic Blood Pressure
Blocks 2 End of Treatment Week 14
102.34 mm HG
Standard Deviation 11.797
102.51 mm HG
Standard Deviation 11.488

SECONDARY outcome

Timeframe: up to 14 weeks

Population: see participant flow section for participants that did not complete blocks

Diastole blood pressure - blood pressure when the heart muscle is between beats. normal range varies by age, sex, height and weight and can range from 34mm Hg to 90mmHg

Outcome measures

Outcome measures
Measure
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
Vital Signs - Diastolic Blood Pressure
Block 1 Baseline Week 0
61.78 mm HG
Standard Deviation 8.773
61.26 mm HG
Standard Deviation 7.882
Vital Signs - Diastolic Blood Pressure
Block 1 End of Treatment Week 6
64.58 mm HG
Standard Deviation 8.638
62.77 mm HG
Standard Deviation 8.609
Vital Signs - Diastolic Blood Pressure
Block 2 Baseline Week 8
62.33 mm HG
Standard Deviation 7.835
61.28 mm HG
Standard Deviation 8.442
Vital Signs - Diastolic Blood Pressure
Blocks 2 End of Treatment Week 14
62.82 mm HG
Standard Deviation 7.325
65.44 mm HG
Standard Deviation 8.699

SECONDARY outcome

Timeframe: up to 14 weeks

Population: see participant flow section for participants that did not complete blocks

Heartbeats per minute. Range varies from 50-205 depending on age and level of activity.

Outcome measures

Outcome measures
Measure
Atomoxetine Then Methylphenidate
n=108 Participants
Block 1 receiving Atomoxetine first, washout period, then Block 2 receiving Methylphenidate
Methylphenidate Then Atomoxetine
n=124 Participants
Block 1 receiving Methylphenidate first, washout period, then Block 2 receiving Atomoxetine
Vital Signs - Pulse
Block 1 Baseline Week 0
78.20 beats per minute
Standard Deviation 12.927
77.49 beats per minute
Standard Deviation 12.365
Vital Signs - Pulse
Block 1 End of Treatment Week 6
84.46 beats per minute
Standard Deviation 14.697
82.05 beats per minute
Standard Deviation 12.915
Vital Signs - Pulse
Block 2 Baseline Week 8
82.96 beats per minute
Standard Deviation 13.931
81.30 beats per minute
Standard Deviation 12.683
Vital Signs - Pulse
Blocks 2 End of Treatment Week 14
84.85 beats per minute
Standard Deviation 13.314
84.31 beats per minute
Standard Deviation 13.095

SECONDARY outcome

Timeframe: up to 14 weeks

Population: data not collected

Measure of socioeconomic status, score calculated from averaging likert responses, lower = worse

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: up to 14 weeks

Population: data not collected

Standardized measure of ADHD symptoms and severity, norm referenced T scores, higher = worse

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: up to 14 weeks

Population: data not collected

Standardized measure of ADHD symptoms and severity, norm referenced T scores, higher = worse

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Measured at screening

Population: data not collected

CBCL Total Score, measure of psychosocial problems, higher is worse.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: up to 14 weeks

Population: data not collected

Measure of social skills, higher score is better. This scale is based on t-scores and does not have psychometrics available.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: up to 14 weeks

Population: data not collected

Measure of fluency in performance of simple mathematics, sum, lower = worse

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Measured daily throughout the study

Population: data not collected

Measure of physical activity

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Measured daily throughout the study

Population: data not collected

Questionnaire, qualitative

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Measured at screening

Population: data not collected

Questionnaire, qualitative designed to collect family history, prenatal environmental influences, and developmental history.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: up to 14 weeks

Population: data not collected

Questionnaire, qualitative assesses symptoms of rebound (moodiness, irritability, aggression, and ADHD symptoms) when the medication wears off at night.

Outcome measures

Outcome data not reported

Adverse Events

Block 1 ATX

Serious events: 0 serious events
Other events: 24 other events
Deaths: 0 deaths

Block 1 MPH

Serious events: 0 serious events
Other events: 35 other events
Deaths: 0 deaths

Block 2 ATX

Serious events: 0 serious events
Other events: 20 other events
Deaths: 0 deaths

Block 2 MPH

Serious events: 0 serious events
Other events: 25 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Block 1 ATX
n=108 participants at risk
Block 1 first four weeks received Atomoxetine
Block 1 MPH
n=124 participants at risk
Block 1 first four weeks received Methylphenidate
Block 2 ATX
n=95 participants at risk
Block 2 (weeks 8 to 13) received Atomoxetine
Block 2 MPH
n=110 participants at risk
Block 2 (weeks 8 to 13) received Methylphenidate
General disorders
Insomnia
4.6%
5/108
12.9%
16/124
3.2%
3/95
12.7%
14/110
Psychiatric disorders
Aggression
5.6%
6/108
4.8%
6/124
5.3%
5/95
3.6%
4/110
Gastrointestinal disorders
Appetite Loss
6.5%
7/108
7.3%
9/124
7.4%
7/95
3.6%
4/110
Psychiatric disorders
Irritability
5.6%
6/108
3.2%
4/124
5.3%
5/95
2.7%
3/110

Additional Information

Dr. Jeffrey H Newcorn

Icahn School of Medicine at Mount Sinai

Phone: 212-659-8705

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place